Biohaven (BHVN) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Biohaven (BHVN) has outperformed Zymeworks (ZYME) over the past year, gaining 27.9% versus a gain of 8.8%. Biohaven is the larger company by market cap ($1.87 billion vs $1.81 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | ZYME |
|---|---|---|
| Share price | $12.39 | $26.14 |
| Market cap | $1.87B | $1.81B |
| 1-day change | -9.23% | -2.68% |
| YTD return | +9.74% | -0.72% |
| 1-year return | +27.86% | +8.83% |
| 5-year return | — | +34.05% |
| P/E ratio (TTM) | — | 49.32 |
| Forward P/E | — | 54.95 |
| EPS (TTM) | $-3.77 | $0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $105.97M |
| Revenue growth (YoY) | — | +38.87% |
| Net income (latest FY) | $-738.82M | $-81.13M |
| Operating margin | — | -87.34% |
| Net margin | — | -76.56% |
| 52-week high | $18.24 | $31.97 |
| 52-week low | $8.03 | $21.52 |
| Distance from 52-week high | -32.07% | -18.24% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +102.82% | +65.61% |
| Average volume | 3.24M | 1.09M |
| Shares outstanding | 151.06M | 68.70M |
| Employees | 274 | 279 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BHVN has outperformed ZYME by 19.0 percentage points over the past year.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 279 employees
BHVN vs ZYME FAQ
Which is bigger, Biohaven or Zymeworks?
Biohaven (BHVN) is larger, with a market capitalization of $1.87B compared with $1.81B for Zymeworks (ZYME).
Which stock has performed better over the past year, BHVN or ZYME?
BHVN returned +27.86% over the past 12 months, compared with +8.83% for ZYME (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.